The present invention relates to the general field of devices and methods for breathing problems such as snoring and sleep apnea. and is particularly concerned with a valved nasal cannula.
The prevalence of breathing disorders during sleep, including snoring and sleep apnea, is relatively high. Such disorders are associated with significant morbidity.
The harsh and rough sound known as snoring is typically caused when a person breathes through his or her mouth during sleep in such a manner so as to cause the soft palate and/or uvula to vibrate, but may also occur when the person breathes through his or her nose. in addition to the irritating snoring sound which may cause potential marital stress, it has been suggested that mouth breathing is unhealthy. Indeed, it contributes to the development of gum diseases such as pyorrhoea and also to an unpleasant dry mouth syndrome.
Sleep apnea is a potentially lethal condition characterized by multiple mixed or obstructed apneas during sleep. Symptoms of sleep apnea include repetitive episodes of inordinately loud snoring and excessive daytime sleepiness.
The characteristic snoring pattern noted during sleep apnea is one in which inspiratory snores gradually increase when obstruction of the upper airway develops. A loud, choking inspiratory gasp then occurs as the respiratory efforts succeed in overcoming the occlusion.
The aroused individual subject to sleep apnea is usually aware of neither the breathing difficulty nor of the accompanying body movements that, at times, violently disturb his or her sleep. Typically, a diagnostic study is necessary for an adequate description of the problematic sleep breathing pattern.
Apneic episodes during sleep are typically defined as cessations of air flow at nose and mouth lasting 10 seconds or more. it can be readily documented by so-called poly-somnographic recordings.
There are varying degrees of apnea differentiated by the frequency of periodic breathing cessation episodes during sleep, and also the degree of hypoxia resulting from the related irregular breathing pattern.
When normal breathing is disrupted during sleep, an increased carbon dioxide level and a reduced oxygen level appear in the blood. The sleeping person is then suddenly aroused. and gasps for air. This gasping for air is often accompanied by a loud snort.
An increased carbon dioxide level in the blood can cause adverse effects on the vital organs. The heart is usually caused to pump harder and at a higher rate in an effort to compensate for the lack of oxygen. Other organs, such as the kidneys and liver are suddenly confronted with increase blood flow and must adjust to cope with this change. This cycle may be repeated many times during a night's rest and often results in a general lack of proper rest and the restorative benefits thereof.
Some of the health related problems associated with sleep apnea include hypertension, stroke, irregular heartbeat, heart attack as well as the psychogenic conditions from the loss of restful sleep.
It is generally believed that the cause to this condition is a narrowing of the airways while sleeping. This is believed to be caused by a collapse of the tissue structures surrounding the airway. There seems, however, to be no consensus as to what tissue structures the condition should he-attributed to and as to why certain tissue structures close.
There are differing locations and patterns of pharyngeal collapse for each person. In addition to the physical findings and properties which characterize the pharynx in individuals with obstructive sleep apnea such as increased. collapsibility, increase compliance, increased resistance and decreased cross-sectional area, the physical properties and spatial relationships of the pharyngeal airway, head and neck, as well as the neuromuscular integrity of the airway and a mechanism of breathing control must also be considered relevant in their contribution to the mechanism. and precipitation of upper airway collapse.
In general, it may be considered that obstructive apnea occurs during sleep when the pharyngeal dilator muscle activity (genioglossus, the infrahyoid muscle and the palatal muscle group) that normally maintain airway potency during inspiration through dilation of the airways, is diminished. When the intraluminal negative pressure of the airway reaches a critical point, the combination of redundant tissues and the loss of pharyngeal muscle tonus cause airway collapse during inspiration. It should, however, be noted that obstruction has also been found to occur during expiration and inspiration.
The prior art is replete with various methods and devices that have been proposed in attempts to cure snoring and sleep apnea. Treatments available for sleep apnea. vary from weight loss to surgical interventions to prosthetic devices. Although weight loss is the most desirable approach, few patients are able to comply with their diets and very few can afford to continue the exposure to the symptoms of sleep apnea for extended periods while losing sufficient weight to reduce or cure the disease.
Surgical approaches are only effective in about 50% of cases. They are also invasive, expensive and may produce undesirable side effects,
The most successful prosthetic device has been the nasal continuous positive airway ventilator or pressure known as “CPAP”. The advantages of the nasal CPAP system are that it produces immediate relief, is non-invasive and can he used while achieving weight loss, hence eliminating the need for surgery.
The CPAP technique, however, suffers front some important drawbacks. One of the primary drawbacks associated with nasal CPAP has been compliance. While nearly all patients are fitted with nasal CPAP as an initial treatment modality, man cease using the system after a few months. At least three primary factors have been identified as the cause for poor compliance amongst individuals using the CPAP system. One such factor is the lack of perfect fit and discomfort of wearing a nasal mask. The positive pressure of the ventilator flow is often mentioned as another factor, Some patients experience an uncomfortable and annoying sensation of forced air stream in their nose and mouth. Also, dry mouth and throat are often cited as the source of dissatisfaction with the sleep apnea ventilators known as CPAP.
Another type of devices used for treating sleep apnea is a valved nasal cannula insertable, in the nostril of an intended user, Such cannulae typically include a body defining a passageway. A valve extends across the passageway and is configured to allow air to flow substantially unaffected into the nose of the intended user, but to restrict any outgoing flow of air so as to provide a backpressure, with the intention of keeping the airways open so as to reduce snoring.
Many such devices have a valve taking the form of a flexible leaflet extending across the passageway and attached to the body at the periphery thereof. This is the case, for example, of some of the nasal cannulae described in U.S. Pat. No. 6,626,179 issued Sep. 30, 2003 to Pedley, and of some of the cannula described in US Patent Application 2006/0150979 of Doshi et al, published Jul. 13, 2006. However, such leaflets may be influenced by gravity as the orientation of the leaflet relatively to its attachment point will influence its dynamic properties, Furthermore, these leaflets present a relatively large lever relatively to their attachment points and therefore have a relatively large response time when transitioning between their “free flowing” configurations to heir “backpressure providing” configurations,
The above-referenced US Patent Application 2006/0150979 presents some valved nasal cannulae that alleviate at least in part these problems by having valves that are supported at the center thereof by a frame extending across the passageway. Also, some of the valves presented in this document are supported by the body of the cannula at two diametrically opposed location and fold in two to let air flow upon inspiration by the intended user. These two types of valves however may lead, to the valve leaflet sticking to itself or to the relatively flat surfaces of the valve support, which again reduces response time and may even lead to valve malfunction.
Another problem of these valves resides in that if the valve RECTIFIED SHEET (RULE 91.1)
becomes detached from the body of the cannula for any reason, the valve may be aspirated by the user of the valve and block the airways of this user.
Accordingly, there exists a need in the industry for an improved valved nasal cannula. An object of the present invention is therefore to provide an improved valved nasal cannula.
In a first broad aspect, the invention provides a valved nasal cannula, the valved nasal cannula being insertable in a nose of an intended user and usable to selectively restrict a flow of air flowing through the valved nasal cannula, the nose having a nostril defining a nostril inlet and a nostril vestibule extending inwardly into the nose from the nostril inlet, the valved nasal cannula comprising:
Advantages of the present invention include that the proposed valved nasal cannula is adapted to provide a positive pressure in the airway using the breathing of the intended user as a source of positive pressure without the need for an external source of energy and/or compressed air. The proposed cannula is designed so as to be relatively easily insertable and retractable into and from the nasal vestibule portion of the nose of the intended user without requiring manual dexterity.
The protective grid serves, among other purposes, to prevent the valve from Obstructing the airways of the intended user should the valve become detached from the cannula body.
Also, the proposed cannula is designed so as to be comfortable once inserted into the nasal vestibule of the intended user. The proposed cannula is designed so as to be substantially fittingly inserted into the nasal vestibule and, in at least some embodiments, to enlarge the latter so as to optimize the breathing passageway.
Also, in some embodiments of the invention, the proposed cannula is designed so as to be resiliently deformable in order to reduce the risk of injury, should the nose of the intended wearer be subjected to an impact while housing the proposed cannula.
The proposed cannula may be used for reducing sleep disorder breathing and/or as a breathing exercise as it may be the case for example in Chronic Obstructive Pulmonary Disease (COPD) affecting the inspiratory muscles. In order to exercise the muscles for such a disease (COPD) the cannula is inserted, for a short period of exercise, upside down into the nasal nostril or preferably a special cannula having a reverse configuration would be used. This configuration allows to induce a resistance to air flow during the inspiration phase rather than at the expiration phase consequently the inspiratory muscles will gain in strength.
The proposed, cannula may optionally be provided with features such as thermal insulation properties in order to reduce the thermal exchange between the airway and the air flowing therethrough, filtering and/or air moisturizing means, active substance dispensing means for dispensing active substances having a stimulating, therapeutic and/or prophylactic effect.
The proposed device is also designed so as to be manufacturable using conventional forms of manufacturing and conventional materials such as a polymeric resin injecting moulding process using suitable hypo-allergic resins so as to provide a nasal cannula that will be economically feasible, long-lasting and relatively trouble-free in operation.
The proposed nasal cannula is also designed so as to optimize the air flow therethrough.
The proposed nasal cannula is also designed so as to reduce the resistance to air flow during the inspiratory phase of breathing and so as to be substantially silent during use.
Other objects, advantages and features of the present, invention will become more apparent upon reading of the following non-restrictive description of preferred embodiments thereof, given by way of example only with reference to the accompanying drawings.
In the appended drawings:
Referring to
The valved nasal cannula 10 is insertable in the nose of the intended user 14 and. usable to selectively restrict a flow of air flowing through the valved nasal cannula 10. The nostril 12 defines a nostril inlet 15 and a nostril vestibule, part of the nasal vestibule 16, the nostril vestibule extending inwardly into the nose from the nostril inlet 15.
As illustrated more specifically in
The cannula body 18 also defines a body inner surface 24 and an opposed body outer surface 26. The cannula body 18 is configured and sized for being substantially snugly fitted in the region of the nasal vestibule 16. The internal tissue of the nasal vestibule 16 is typically considered to be less sensitive to tactile stimulation than downstream nasal tissue and, hence, less susceptible of sending nociceptive signals to the brain upon a foreign body being inserted therein.
The cannula body 18 typically has a substantially frusto-conical configuration defining a cannula proximal end 28 and a longitudinally opposed cannula distal end 30. The cannula body 18 is, at least in part. insertable in the nostril 12 with the cannula proximal end 28 positioned inside the nostril vestibule substantially spaced apart from the nostril inlet 15 and the cannula distal end 30 positioned substantially adjacent the nostril inlet 15, In other words, the cannula proximal end 28 is adapted to be positioned nearer to the sinuses of the intended wearer while the cannula distal end 30 is adapted to be positioned nearer to the inlet of the nostril 12. Typically, the external diameter of the cannula proximal end 28 is smaller than that of the cannula distal end 30. Therefore, in these embodiments, the body outer surface 26 is tapered in a direction leading from the cannula distal end 30 towards the cannula proximal end 28.
As illustrated more specifically in
surface-to-longitudinal axis angle 32 could vary without departing from the scope of the present invention. Typically, the cannula body 18 is configured and sized for providing a radial outward pressure so as to slightly increase the size of the nasal vestibule 16.
The outer surface-to-longitudinal axis angle 32, as well as the diameter of the cannula body 18 and its length are typically chosen for a given user in order to ensure a comfortable yet substantially snug fit in the nasal vestibule 16 of the intended user in order to ensure that the cannula body 18 remains in proper alignment therewith.
The substantially frustro-conical configuration of the body outer surface 26 allows for such a comfortable yet snug fit taking into consideration the anatomical configuration of the internal surface of the nasal vestibule 16 since it substantially increases the probability of having a substantially uniform or constant contact with the internal surface of the nasal vestibule 16.
In order to reduce the risks of creating a localized pressure onto the relatively sensitive tissues of the nasal cavity, the body outer surface 26 is typically provided with a substantially smooth texture. Also, the body outer surface 26 is typically provided with a substantially resiliently deformable characteristic. The cannula body 18 may be made out of an integral material having such characteristics or, alternatively, the body outer surface 26 may be coated with a substantially resiliently deformable material.
Typically, the cannula body 18, as a whole, is made out of a substantially resiliently deformable material and provides resiliency so as to be able to temporarily deform upon an impact of a predetermined magnitude being imparted thereon so as to reduce the risk of injury to the internal tissues of the
nose of the intended user 14 should an impact be imparted externally on the nose of the intended user 14. More specifically, the cannula body 18 is substantially resiliently deformable between a body undeformed configuration and a body deformed configuration, whereby the cannula body 18 is able to temporarily deform from the body undeformed configuration to the body deformed configuration upon an impact of the predetermined magnitude being imparted thereon
In at least one embodiment of the invention, the cannula body 18 is made out first of a resiliently deformable material while the body outer surface 26 is coated with a second resiliently deformable material. The characteristics of the first and second resiliently deformable materials may be identical or different without departing from the scope of the present invention.
In some embodiments of the invention, the cannula body 18 and/or the coating on the body external surface 26 is made of an hypo-allergic material such as a latex-free polymeric resin so as to reduce the risk of creating an allergic reaction once inserted into the nose of the intended user.
Also. in at least some embodiments of the invention, the cannula body 18 and/or the coating on the body external surface 26 is made out of a heat insulating material so as to reduce the heat transfer between the mucosa of the nose of the intended user and the air flowing through the nasal cannula. The reduced heat transfer may allow for cooler air to reach internal tissues so as to reduce oedema. thereof.
The nasal cannula 10 further includes a valve for selectively restricting the flow of air through the cannula passageway 20, The valve is operatively coupled to the cannula body for selectively restricting the flow of air through the cannula passageway. Typically, the valve is a diaphragm-type valve and is positioned in the cannula passageway 20 substantially spaced apart from both the cannula proximal and distal ends 28 and 30, although other types and positions of the valve could be used without departing from the scope of the present invention.
In the embodiments shown throughout the drawings, and as seen for example in
As illustrated more specifically in
As illustrated more specifically in
The diaphragm disc 34 is provided with a corresponding a mounting aperture 39 extending therethrough, the mounting aperture 39 having a radius substantially smaller than the radius of the retaining stein 42, and more specifically of the retaining lip 46. The resilient nature of the diaphragm disc 34 allows the diaphragm disc 34 to be stretched radially so as to allow the mounting aperture 39 to be fitted over the retaining prong 44 into the discreceiving spacing 48. This configuration of the valve allows to replace the diaphragm disc 34 should the diaphragm disc 34 become damaged, or should the needs of the intended user 14 change. For example, the diaphragm disc 34 could be exchanged for a diaphragm disc 34 having a different rigidity, or for a diaphragm disc 34 including a substance able to diffuse into the airflow passing thereby.
The diaphragm disc 34 is located closer to the body proximal end 28 than the diaphragm frame 36. Therefore, the resilient nature of the diaphragm disc 34 allows the latter to bend when subjected to a pressure imparted thereon. Typically, during the inspiration phase of breathing, the disc deforms substantially freely from a substantially flat closed configuration wherein it rests on the spokes 38 to an opened configuration shown in
In some embodiments of the invention, the diaphragm frame 36 and the diaphragm disc 34 have dimensions, configurations and deformation properties such that a substantially constant backpressure is exerted by the diaphragm disc 34 upon the intended user expiring air from the cannula proximal end towards 28 the cannula distal end 30 for a predetermined range of expiration flow rate. For example, the substantially constant backpressure is from about 0.1 cm H2O to about 100 cm H2O, and in some embodiments from about 0.5 cm H2O to about 20 cm H2O. In some
embodiments of the invention, the predetermined range of expiration flow rate is from about 0.5 L/min to about 60 L/min, and in some embodiments, from about 10 L/min to about 40 L/min.
Referring back to
The number of spokes 38, their thickness, the spacing therebetween, and the thickness and material of the diaphragm disc 34 are typically calibrated so as to provide a predetermined resistance to the flow of air during the expiration phase of breathing. During the expiration phase of breathing, the diaphragm disc 34 is pushed back from its opened configuration shown in
Upon the pressure building up in the airway upstream from the nasal cannula 10 as a result of the air being blocked from flowing through the nasal passageway during the initial stage of the expiration phase of breathing, the internal pressure will eventually cause the diaphragm disc 34 to deform into a restricting configuration shown in
Hence, by using a substantially centrally anchored diaphragm disc 34 adapted to deform substantially about its periphery, a substantially constant resistance to air flow is provided during both the inspiration and expiration phases of breathing mainly because of the resilient nature of the diaphragm disc 34. The resistance to air flow during the inspiratory phase will be less than the one during the expiratory phase of breathing. Furthermore, the delay of action of the valve is relatively short. Also, since the air will flow substantially peripherally, the air is distributed along the internal tissues of the nose hence improving the naturally occurring of heat exchange and humidification of the air flowing there through. Also, the diaphragm disc deflecting substantially peripherally and abutting against relatively small contact surfaces will have a tendency to be substantially silent and to have a relatively fast response time when the intended user switches between inspiration and expiration breathing.
In some embodiments of the invention, as seen in
In addition to, or independently from the valve, the nasal cannula 10 may be provided with a filtering medium and/or an air treating medium. For example, the nasal cannula 10 may be provided with an HEPA filter located within the cannula body 18 or any other suitable filter. The nasal
cannula 10 may also be provided with a heat and/or humidity exchanger. The nasal cannula 10 may also be provided with a material mounted therein for dispensing a pharmaceutically active substance, an air treatment substance or any other suitable substance adapted to be activated by the breathing of the user and/or intrinsically active.
As seen in
As seen in
Mounting of the mobile spoke 38″ may be achieved by having a mounting shaft 56 extending substantially longitudinally from the center of the fixed spoke 38. The mobile spoke 38″ is mounted to a substantially longitudinally extending sleeve 56 mounted onto the mounting shaft 56. The mobile spoke 38″ defines notches 60 extending substantially radially inwardly thereinto. The cannula body 18″ defines substantially radially inwardly extending ledges 62 located so as to engage the notches 60. The ledges 62 define recesses 68 for receiving the notches 60 at circumferentially spaced
apart locations, thereby allowing to adjust in discrete steps the position of the mobile spoke 38″ relatively to the fixed spoke 38.
In some embodiments of the invention. as illustrated in
Although the present invention has been described hereinabove by way of preferred embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention as defined in the appended claims.
Number | Date | Country | Kind |
---|---|---|---|
0610171.1 | May 2006 | GB | national |
This application is a continuation of U.S. application Ser. No. 12/301,157, filed Mar. 16, 2009, which was the National Stage of international Application No, PCT/CA2007/000992. filed May 18, 2007. the entire disclosure of which is hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
628111 | McHatton | Jul 1899 | A |
669098 | Overshiner | Mar 1901 | A |
675275 | Gunning | May 1901 | A |
746869 | Moulton | Dec 1903 | A |
774446 | Moulton | Nov 1904 | A |
810617 | Carence | Jan 1906 | A |
1819884 | Fores | Aug 1931 | A |
1867478 | Stelzner | Jul 1932 | A |
2198959 | Clarke | Apr 1940 | A |
2237954 | Wilson | Apr 1941 | A |
2264153 | Rowe | Nov 1941 | A |
2274886 | Carroll | Mar 1942 | A |
2282681 | Stotz | May 1942 | A |
2335936 | Hanlon | Dec 1943 | A |
2433565 | Korman | Dec 1947 | A |
2448724 | McGovney | Sep 1948 | A |
2672138 | Carlock | Mar 1954 | A |
2751906 | Irvine | Jun 1956 | A |
2777442 | Zelano | Jan 1957 | A |
3145711 | Beber | Aug 1964 | A |
3370305 | Goott et al. | Feb 1968 | A |
3424152 | Kuhlman | Jan 1969 | A |
3451392 | Cook et al. | Jun 1969 | A |
3463149 | Albu | Aug 1969 | A |
3513839 | Vacante | May 1970 | A |
3556122 | Laerdal | Jan 1971 | A |
3695265 | Brevik | Oct 1972 | A |
3710799 | Caballero | Jan 1973 | A |
3722509 | Nebel | Mar 1973 | A |
3747597 | Olivera | Jul 1973 | A |
3884223 | Keindl | May 1975 | A |
3902621 | Hidding | Sep 1975 | A |
4004584 | Geaney | Jan 1977 | A |
4030491 | Mattila | Jun 1977 | A |
4040428 | Clifford | Aug 1977 | A |
4054134 | Kritzer | Oct 1977 | A |
4062358 | Kritzer | Dec 1977 | A |
4120299 | Russo | Oct 1978 | A |
4143872 | Havstad et al. | Mar 1979 | A |
4226233 | Kritzer | Oct 1980 | A |
4240420 | Riaboy | Dec 1980 | A |
4249527 | Ko et al. | Feb 1981 | A |
4267831 | Aguilar | May 1981 | A |
4325366 | Tabor | Apr 1982 | A |
4327719 | Childers | May 1982 | A |
RE31040 | Possis | Sep 1982 | E |
4354489 | Riaboy | Oct 1982 | A |
4403616 | King | Sep 1983 | A |
4456016 | Nowacki et al. | Jun 1984 | A |
4487207 | Fitz | Dec 1984 | A |
4533137 | Sonne | Aug 1985 | A |
4582058 | Depel et al. | Apr 1986 | A |
4601465 | Roy | Jul 1986 | A |
4739987 | Nicholson | Apr 1988 | A |
4822354 | Elosegui | Apr 1989 | A |
4854574 | Larson et al. | Aug 1989 | A |
4862903 | Campbell | Sep 1989 | A |
4878513 | Ashby | Nov 1989 | A |
4908028 | Colon et al. | Mar 1990 | A |
4944310 | Sullivan | Jul 1990 | A |
4973047 | Norell | Nov 1990 | A |
4979505 | Cox | Dec 1990 | A |
4984302 | Lincoln | Jan 1991 | A |
4984581 | Stice | Jan 1991 | A |
5033312 | Stupecky | Jul 1991 | A |
5038621 | Stupecky | Aug 1991 | A |
5059208 | Coe | Oct 1991 | A |
5078739 | Martin | Jan 1992 | A |
5092781 | Casciotti et al. | Mar 1992 | A |
5117820 | Robitaille | Jun 1992 | A |
5197980 | Gorshkov et al. | Mar 1993 | A |
5255687 | McKenna | Oct 1993 | A |
5383470 | Kolbly | Jan 1995 | A |
5385542 | Rawlings | Jan 1995 | A |
5391205 | Knight | Feb 1995 | A |
5392773 | Bertrand | Feb 1995 | A |
5394867 | Swann | Mar 1995 | A |
5415660 | Campbell et al. | May 1995 | A |
5425359 | Liou | Jun 1995 | A |
5459544 | Emura | Oct 1995 | A |
RE35339 | Rapoport | Oct 1996 | E |
5562641 | Flomenblit et al. | Oct 1996 | A |
5568808 | Rimkus | Oct 1996 | A |
5607469 | Frey | Mar 1997 | A |
5649533 | Oren | Jul 1997 | A |
5665104 | Lee | Sep 1997 | A |
5740798 | McKinney | Apr 1998 | A |
5743256 | Jalowayski | Apr 1998 | A |
5763979 | Mukherjee et al. | Jun 1998 | A |
5775335 | Seal | Jul 1998 | A |
5782896 | Chen et al. | Jul 1998 | A |
5797920 | Kim | Aug 1998 | A |
5816241 | Cook | Oct 1998 | A |
5865170 | Moles | Feb 1999 | A |
5876434 | Flomenblit et al. | Mar 1999 | A |
5890998 | Hougen | Apr 1999 | A |
5899832 | Hougen | May 1999 | A |
5910071 | Hougen | Jun 1999 | A |
5911756 | Debry | Jun 1999 | A |
5929286 | Krumpelt et al. | Jul 1999 | A |
5947119 | Reznick | Sep 1999 | A |
5954766 | Zadno-Azizi et al. | Sep 1999 | A |
5957978 | Blom | Sep 1999 | A |
5992006 | Datsikas | Nov 1999 | A |
6004342 | Filis | Dec 1999 | A |
6083141 | Hougen | Jul 2000 | A |
6110861 | Krumpelt et al. | Aug 2000 | A |
D430667 | Rome | Sep 2000 | S |
6119690 | Pantaleo | Sep 2000 | A |
6177482 | Cinelli et al. | Jan 2001 | B1 |
6258100 | Alferness et al. | Jul 2001 | B1 |
6287290 | Perkins et al. | Sep 2001 | B1 |
6293951 | Alferness et al. | Sep 2001 | B1 |
6369126 | Cinelli et al. | Apr 2002 | B1 |
6386197 | Miller | May 2002 | B1 |
6443944 | Doshi et al. | Sep 2002 | B1 |
6484725 | Chi | Nov 2002 | B1 |
6558831 | Doshi et al. | May 2003 | B1 |
6561188 | Ellis | May 2003 | B1 |
6562057 | Santin | May 2003 | B2 |
6564800 | Olivares | May 2003 | B1 |
6568387 | Davenport et al. | May 2003 | B2 |
6585639 | Kotmel et al. | Jul 2003 | B1 |
6592594 | Rimbaugh et al. | Jul 2003 | B2 |
6595215 | Wood | Jul 2003 | B2 |
6626172 | Karow et al. | Sep 2003 | B1 |
6626179 | Pedley | Sep 2003 | B1 |
6632554 | Doshi et al. | Oct 2003 | B2 |
6679264 | Deem et al. | Jan 2004 | B1 |
6722360 | Doshi | Apr 2004 | B2 |
6756144 | Issacci et al. | Jun 2004 | B2 |
6863066 | Ogle | Mar 2005 | B2 |
6872439 | Fearing et al. | Mar 2005 | B2 |
6921574 | Cinelli et al. | Jul 2005 | B2 |
6997177 | Wood | Feb 2006 | B2 |
7001684 | Doshi et al. | Feb 2006 | B2 |
7011723 | Full et al. | Mar 2006 | B2 |
7047969 | Noble | May 2006 | B2 |
7156098 | Dolezal et al. | Jan 2007 | B2 |
7156099 | Jenkins | Jan 2007 | B1 |
7175723 | Jones et al. | Feb 2007 | B2 |
7178524 | Noble | Feb 2007 | B2 |
7201169 | Wilkie et al. | Apr 2007 | B2 |
D542407 | Stallard et al. | May 2007 | S |
7211342 | Issacci et al. | May 2007 | B2 |
7263996 | Yung Ho | Sep 2007 | B2 |
7334581 | Doshi | Feb 2008 | B2 |
7493902 | White et al. | Feb 2009 | B2 |
7506649 | Doshi et al. | Mar 2009 | B2 |
7615304 | Ferrall et al. | Nov 2009 | B2 |
7658189 | Davidson et al. | Feb 2010 | B2 |
7676276 | Karell | Mar 2010 | B2 |
7678132 | Abbott et al. | Mar 2010 | B2 |
7708017 | Davidson et al. | May 2010 | B2 |
7735491 | Doshi et al. | Jun 2010 | B2 |
7735492 | Doshi et al. | Jun 2010 | B2 |
7775210 | Schobel et al. | Aug 2010 | B2 |
7798148 | Doshi | Sep 2010 | B2 |
7806120 | Loomas et al. | Oct 2010 | B2 |
7856979 | Doshi et al. | Dec 2010 | B2 |
7987852 | Doshi et al. | Aug 2011 | B2 |
8281557 | Doshi et al. | Oct 2012 | B2 |
20010051799 | Ingenito | Dec 2001 | A1 |
20010052344 | Doshi | Dec 2001 | A1 |
20010056274 | Perkins et al. | Dec 2001 | A1 |
20020062120 | Perkins et al. | May 2002 | A1 |
20020177031 | Doshi et al. | Nov 2002 | A1 |
20020177871 | Santin | Nov 2002 | A1 |
20030004498 | Doshi et al. | Jan 2003 | A1 |
20030054215 | Doshi et al. | Mar 2003 | A1 |
20030106555 | Tovey | Jun 2003 | A1 |
20030124401 | Issacci et al. | Jul 2003 | A1 |
20030140925 | Sapienza et al. | Jul 2003 | A1 |
20030154988 | Devore et al. | Aug 2003 | A1 |
20030158515 | Gonzalez et al. | Aug 2003 | A1 |
20030195552 | Santin | Oct 2003 | A1 |
20030209247 | O'Rourke | Nov 2003 | A1 |
20040016432 | Genger et al. | Jan 2004 | A1 |
20040020493 | Wood | Feb 2004 | A1 |
20040067235 | Doshi | Apr 2004 | A1 |
20040141875 | Doshi | Jul 2004 | A1 |
20040146773 | Doshi et al. | Jul 2004 | A1 |
20040194779 | Doshi | Oct 2004 | A1 |
20040194780 | Doshi | Oct 2004 | A1 |
20040209134 | Issacci et al. | Oct 2004 | A1 |
20040261791 | Horian | Dec 2004 | A1 |
20050003262 | Doshi | Jan 2005 | A1 |
20050011524 | Thomlinson et al. | Jan 2005 | A1 |
20050051770 | Ando et al. | Mar 2005 | A1 |
20050133026 | Seleznev et al. | Jun 2005 | A1 |
20050284479 | Schrader et al. | Dec 2005 | A1 |
20060032497 | Doshi | Feb 2006 | A1 |
20060085027 | Santin et al. | Apr 2006 | A1 |
20060096596 | Occhialini et al. | May 2006 | A1 |
20060144398 | Doshi et al. | Jul 2006 | A1 |
20060150978 | Doshi et al. | Jul 2006 | A1 |
20060150979 | Doshi et al. | Jul 2006 | A1 |
20060283461 | Lubke et al. | Dec 2006 | A1 |
20070095349 | Hansmann et al. | May 2007 | A1 |
20070175478 | Brunst | Aug 2007 | A1 |
20070227542 | Kashmakov et al. | Oct 2007 | A1 |
20070277832 | Doshi et al. | Dec 2007 | A1 |
20070283962 | Doshi et al. | Dec 2007 | A1 |
20070295338 | Loomas et al. | Dec 2007 | A1 |
20080173309 | Doshi | Jul 2008 | A1 |
20080178874 | Doshi et al. | Jul 2008 | A1 |
20080221470 | Sather et al. | Sep 2008 | A1 |
20080275424 | Doshi et al. | Nov 2008 | A1 |
20090011323 | Guan et al. | Jan 2009 | A1 |
20090145441 | Doshi et al. | Jun 2009 | A1 |
20090145788 | Doshi et al. | Jun 2009 | A1 |
20090194100 | Minagi | Aug 2009 | A1 |
20090194109 | Doshi et al. | Aug 2009 | A1 |
20090308398 | Ferdinand et al. | Dec 2009 | A1 |
20090308402 | Robitaille | Dec 2009 | A1 |
20090320851 | Selvarajan et al. | Dec 2009 | A1 |
20100147308 | Doshi et al. | Jun 2010 | A1 |
20100234789 | Batiste et al. | Sep 2010 | A1 |
20100234880 | Abbott et al. | Sep 2010 | A1 |
20100331777 | Danielsson | Dec 2010 | A1 |
20110005520 | Doshi et al. | Jan 2011 | A1 |
20110005528 | Doshi et al. | Jan 2011 | A1 |
20110005529 | Doshi et al. | Jan 2011 | A1 |
20110005530 | Doshi et al. | Jan 2011 | A1 |
20110218451 | Lai et al. | Sep 2011 | A1 |
20120111340 | Robitaille | May 2012 | A1 |
20130081637 | Foley et al. | Apr 2013 | A1 |
Number | Date | Country |
---|---|---|
1 157 663 | Nov 2001 | EP |
1 917 993 | May 2008 | EP |
2 210 109 | Jul 1974 | FR |
2 610 830 | Aug 1988 | FR |
2 126 101 | Mar 1984 | GB |
2 176 406 | Dec 1986 | GB |
2 324 729 | Nov 1998 | GB |
WO 8705798 | Oct 1987 | WO |
WO 9012614 | Nov 1990 | WO |
WO 9517220 | Jun 1995 | WO |
WO 9533520 | Dec 1995 | WO |
WO 0029066 | May 2000 | WO |
WO 0050121 | Aug 2000 | WO |
WO 0067848 | Nov 2000 | WO |
WO 0102042 | Jan 2001 | WO |
WO 0113839 | Mar 2001 | WO |
WO 0113908 | Mar 2001 | WO |
WO 0149371 | Jul 2001 | WO |
WO 0187170 | Nov 2001 | WO |
WO 0238038 | May 2002 | WO |
WO 2004060438 | Jul 2004 | WO |
WO 2004060438 | Jul 2004 | WO |
WO 2004096110 | Nov 2004 | WO |
WO 2006063339 | Jun 2006 | WO |
WO 2006063339 | Jun 2006 | WO |
WO 2007023607 | Mar 2007 | WO |
WO 2007129814 | Nov 2007 | WO |
WO 2007134458 | Nov 2007 | WO |
Entry |
---|
Extended European Search Report for European Application No. 12152742.8, dated Jul. 18, 2012, 11 pages. |
International Search Report in International Application No. PCT/CA2007/000922, dated Aug. 14, 2007, 2 pages. |
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/IB2012/001929, dated Jan. 16, 2013, 10 pages. |
European Search Report for Application No. 12835151.7 dated Jan. 14, 2016 (6 pages). |
Number | Date | Country | |
---|---|---|---|
20120111340 A1 | May 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12301157 | US | |
Child | 13349068 | US |